Effect of a functional polymorphism in the pre-miR-146a gene on the risk and prognosis of renal cell carcinoma

被引:10
作者
Huang, Zhilong [1 ,2 ]
Lu, Zhanpeng [3 ]
Tian, Jingchang [4 ]
Wang, Guangjian [5 ]
Gao, Zhenli [6 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Urol, Jinan 250021, Shandong, Peoples R China
[2] Lanling Cty Peoples Hosp, Dept Urol, Lanling 277799, Shandong, Peoples R China
[3] Jining 1 Peoples Hosp, Dept Urol, Jining 528000, Shandong, Peoples R China
[4] First Hosp Qiqihaer, Dept Urol, Qiqihar 161000, Heilongjiang, Peoples R China
[5] Linyi Peoples Hosp, Dept Urol, Linyi 276000, Shandong, Peoples R China
[6] Yantai Yuhuangding Hosp, Dept Urol, Yantai 264000, Shandong, Peoples R China
关键词
microRNA-146a; polymorphism; risk; prognosis; renal cell carcinoma; APOPTOTIC DEATH; CANCER-RISK; EXPRESSION; MIR-146A; PROLIFERATION; MICRORNAS; ACTIVATION; VARIANTS; SURVIVAL; NOTCH1;
D O I
10.3892/mmr.2015.4260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs) are non-coding RNAs that function as regulators of tumor suppressors and oncogenes. A G>C polymorphism (rs2910164) in the miR-146a precursor sequence leads to a functional change associated with a risk for various types of malignancy. The role of this single nucleotide polymorphism in the pathogenesis of renal cell carcinoma (RCC) has not yet been examined. The present study evaluated the association between rs2910164 genotypes and the risk and prognosis of RCC in a population comprised of 421 RCC cases and 432 controls. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for rs2910164 genotypes according to case status. Cox proportional hazards regression modeling was used to estimate hazards ratios and 95% CIs according to the genotypes among the RCC patients. It was found that the rs2910164 GG and GC genotypes were associated with an increased risk of RCC only in senior subjects (>57-years old; adjusted OR=1.59, 95% CI=1.04-2.43). Furthermore, the GC and GG genotypes were associated with a poorer survival rate among patients with RCC compared with the CC genotype (P=0.002). In conclusion, the observed association between the GG and GC genotype and poorer survival rate of RCC was at least partially mediated by the decreased expression of miR-146a.
引用
收藏
页码:6997 / 7004
页数:8
相关论文
共 39 条
[1]   MicroRNAs: Novel Biomarkers for Human Cancer [J].
Bartels, Claudine L. ;
Tsongalis, Gregory J. .
CLINICAL CHEMISTRY, 2009, 55 (04) :623-631
[2]  
Brito C, 1999, J IMMUNOL, V162, P3356
[3]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[4]   Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[5]  
Chae YS, 2013, ANTICANCER RES, V33, P3233
[6]   P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2 [J].
Chen, Lei ;
Zhang, Run ;
Li, Peng ;
Liu, Yi ;
Qin, Kun ;
Fa, Zhi-qiang ;
Liu, Yi-jing ;
Ke, Yi-quan ;
Jiang, Xiao-dan .
NEUROSCIENCE LETTERS, 2013, 534 :327-332
[7]   Epidemiology and risk factors for kidney cancer [J].
Chow, Wong-Ho ;
Dong, Linda M. ;
Devesa, Susan S. .
NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257
[8]   Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA [J].
Duan, Ranhui ;
Pak, ChangHui ;
Jin, Peng .
HUMAN MOLECULAR GENETICS, 2007, 16 (09) :1124-1131
[9]   Original and reviewed nuclear grading according to the Fuhrman system - A multivariate analysis of 388 patients with conventional renal cell carcinoma [J].
Ficarra, V ;
Martignoni, G ;
Maffei, N ;
Brunelli, M ;
Novara, G ;
Zanolla, L ;
Pea, M ;
Artibani, W .
CANCER, 2005, 103 (01) :68-75
[10]   The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis [J].
Gao, Lin-Bo ;
Bai, Peng ;
Pan, Xin-Min ;
Jia, Jing ;
Li, Li-Juan ;
Liang, Wei-Bo ;
Tang, Ming ;
Zhang, Lu-Shun ;
Wei, Yong-Gang ;
Zhang, Lin .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) :571-574